Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Bridging Therapy's effects on clinical outcomes after commercial BCMA CAR T-cell therapy used in the standard of care treatment of relapsed and refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAmber FengESEmily SellarsMMMelissa Martin

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows bridging therapy affects clinical outcomes in relapsed multiple myeloma post CAR T-cell therapy, indicating need for optimal strategies.

Key Points

  • To evaluate the effects of bridging therapy on clinical outcomes in patients with relapsed and refractory multiple myeloma receiving CAR T-cell therapy.
  • Conducted a retrospective chart review of 69 patients with RRMM receiving CAR T therapy.
  • Categorized patients by bridging regimens: Selinexor-based, bispecific T-cell engager, cytotoxic chemotherapy, or biological myeloma therapeutics.
  • Assessed responses using International Myeloma Working Group criteria and performed statistical analysis.
  • Patients receiving cytotoxic chemotherapy had inferior responses and increased supportive care needs.
  • Bispecific T-cell engager bridging achieved deeper pre-infusion responses but resulted in concerning long-term outcomes.
  • Patients with progressive disease at bridging had higher rates of Cytokine Release Syndrome.

Cite This Study

Feng et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e157https://doi.org/10.1182/blood-2025-6379
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma2026
  2. 2Outcome of bridging therapy in chimeric antigen receptor T cell treatment for Relapsed/Refractory B-cell non-Hodgkin lymphoma: A retrospective study.2025
  3. 3Efficacy and hematopoietic recovery of high-dose melphalan with stem cell rescue as bridging to CAR-T compared with non-intensive bridging in relapsed/refractory multiple myeloma.2026
  4. 4Understanding the Role and Clinical Management of Bridging Therapy During CAR T-Cell Therapy for Relapsed or Refractory Multiple Myeloma2025 · 4 citations
  5. 5Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter2025